HAEMATO AG

HAEMATO PHARM GmbH

HAEMATO PHARM GmbH specializes in the manufacture and sale of generics and EU original medicines. With its product portfolio, the company focuses on five major therapeutic areas: HIV / AIDS, Neurology, Oncology, Rheumatology and Urology.

HAEMATO MED GmbH

HAEMATO MED GmbH is an innovative healthcare company specializing in the development and commercialization of pharmaceutical, medical and medical devices for aesthetic surgery and cosmetic dermatology.

HAEMATO AG

HAEMATO AG is a publicly traded pharmaceutical company focusing on the growth markets of high-end specialty pharmaceuticals in the indication areas of oncology and HIV as well as in the areas of rheumatism, neurology and cardiovascular diseases. In addition, the in-house development of innovative medical devices for the beauty market was started. HAEMATO AG assumes that first products will hit the market in the coming year, which has already created the basis for further growth and additional income.

News

We inform you about the current business development of HAEMATO AG and about our investor relations activities.

According to the preliminary IFRS financial statements for the 2020 financial year, HAEMATO AG increased its revenue by 20.5 % to EUR 238.3 million and increased EBITDA by 74.8 % to EUR 3.3 million

by HAEMATO AG | Apr 21, 2021 | Investor News

Corporate News of HAEMATO AG: According to the preliminary IFRS financial statements for the 2020 financial year, HAEMATO AG increased its revenue by 20.5 % to EUR 238.3 million and increased EBITDA by 74.8 % to EUR 3.3 million. In the 2020 financial year, HAEMATO AG,...

HAEMATO AG successfully completes capital increase

by HAEMATO AG | Mar 29, 2021 | Ad-Hoc Announcement

HAEMATO AG (ISIN: DE000A289VV1, WKN: A289VV) has successfully completed the capital increase which was announced on March 24, 2021. The capital increase was oversubscribed. The Company increased its share capital by € 475,391.00 to € 5,229,307.00 by issuing a total of...

HAEMATO AG plans cash capital increase to finance private label business

by HAEMATO AG | Mar 24, 2021 | Ad-Hoc Announcement

HAEMATO AG plans cash capital increase to finance private label businessHAEMATO AG resolves to carry out a cash capital increase using the Authorized Capital 2018 with exclusion of subscription rights in the amount of up to 10% of the share capital to finance the...

Click here for more news

Publications

Get an overview of the current status and development of HAEMATO AG. Here you will find information on the current status of the Group and on developments in recent years.

Read the Reports